|
| Press Releases |
|
 |
|
| Thursday, May 23, 2024 |
|
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
| Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
| Wednesday, May 22, 2024 |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
| Wednesday, May 15, 2024 |
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Monday, May 13, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
| Thursday, April 18, 2024 |
|
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
| Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
| Wednesday, April 17, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
| Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
|
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は本日、日本において自社創製の抗てんかん剤「フィコンパ(R)」（一般名：ペランパネル水和物、海外製品名：「Fycompa(R)」)の点滴静注用製剤について新発売したことをお知らせします。 more info >> |
|
| Wednesday, April 3, 2024 |
|
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
| Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
| Monday, April 1, 2024 |
|
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
| Friday, March 29, 2024 |
|
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Paying Off Debt but Still Want to Save? Here's How to Manage Both
May 18, 2026 23:30 HKT/SGT
|
|
|
DK88 Launches New Online iGaming App for Malaysia and Singapore
May 18, 2026 22:40 HKT/SGT
|
|
|
'Hong Kong Cinema @ CANNES 2026': Hong Kong's role as a bridge between global and Asian film markets
May 18, 2026 21:52 HKT/SGT
|
|
|
Carbonverse Pioneers a New Ecosystem of "Carbon Assets + Digital Wallet + Use-to-Earn"
May 18, 2026 21:45 HKT/SGT
|
|
|
Carbonverse打造「碳资产+数字钱包+使用即挖矿」新生态
May 18, 2026 21:45 HKT/SGT
|
|
|
Tyson Fury, The Gypsy King, Joins Datavault AI as International Spokesperson to Champion Athlete Data Monetization
May 18, 2026 21:37: JST
|
|
|
「吉普賽之王」泰森·富里加入 Datavault AI 擔任國際代言人，致力推動運動員數據變現
May 18, 2026 20:37 HKT/SGT
|
|
|
“吉普赛之王”泰森·富里加盟Datavault AI，担任国际形象大使，致力于推动运动员数据变现
May 18, 2026 20:37 HKT/SGT
|
|
|
Tyson Fury, The Gypsy King, Joins Datavault AI as International Spokesperson to Champion Athlete Data Monetization
May 18, 2026 20:37 HKT/SGT
|
|
|
'Hong Kong Cinema @ CANNES 2026': Hong Kong's role as a bridge between global and Asian film markets
May 18, 2026 19:19: JST
|
|
|
Ashikaga Bank launches Fujitsu's service supporting digitalization of Inheritance Procedure
May 18, 2026 18:13 JST
|
|
|
Sharp to Exhibit at The 3rd SPEXA - Space Business Expo
May 18, 2026 17:34 JST
|
|
|
Your Go-To Travel Checklist for Smarter, Reward-Focused Travel Planning
May 18, 2026 16:32 HKT/SGT
|
|
|
Tabor Redefines Anti-Drone Testing with Software-Defined SDR Platform
May 18, 2026 16:30 HKT/SGT
|
|
|
MHIEC Receives Waste Treatment Technology Verification Report from JESC for Its Fluidized Bed-type Gasification and Reforming System
May 18, 2026 17:17 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
